The R & D cost is about 7.3 million yuan, and Kelun pharmaceutical is the first to pass the consistency evaluation

On April 10, Kelun pharmaceutical released an enterprise announcement that its subsidiary Hunan Kelun Pharmaceutical Co., Ltd recently obtained the approval document for supplementary drug application of the chemical "Cefalexin capsule" approved and issued by the State Drug Administration, which was the first to pass the consistency evaluation Basic information of drug name: Cefalexin capsule dosage form: capsule specification: 0.125g, 0.25g, 0.5g application items: domestic drug registration conformity assessment registration classification: chemical applicant: Approval conclusion of Hunan Kelun Pharmaceutical Co., Ltd.: after examination, the product passed the conformity assessment of quality and efficacy of generic drugs Cephalosporin is the first generation cephalosporin It is mainly used in the treatment of mild infection caused by sensitive bacteria It is mainly used in the treatment of acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory infections, otitis media, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria Cefalexin has the advantages of good oral absorption, small toxicity and wide antibacterial spectrum It is recommended as the first-line drug by the guide of nice / Phe in 2018guide: prescription of antibiotics for urinary tract infection related to catheter Meanwhile, the 2015 edition of the guiding principles for clinical application of antibiotics recommends that the first generation of Cefalexin should be selected or optional for acute bacterial respiratory tract infection, urinary tract infection, skin and soft tissue infection Medication Cefalexin capsule has entered the national basic drug catalog and national medical insurance category a catalog According to the statistics of open network data, the sales volume of China in 2017 was about 186 million yuan Kelun pharmaceutical is the first in China to pass the consistency evaluation of this variety Up to now, according to the announcement, Kelun pharmaceutical has invested about 7.3 million yuan in the consistency evaluation project of Cefalexin Capsules.